All sponsors

Sun Pharmaceutical Industries Limited

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO80%

Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +30.0 months). See all sponsors →

Open Sun Pharmaceutical Industries Limited on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Tildrakizumab
NCT03997786
P2/3Active, not recruitingModerate-to-severe Chronic Plaque Psoriasis1352025-04-07 (+17 mo)
TILD
NCT04314531
P3Active, not recruitingActive Psoriatic Arthritis2962025-06-04 (+49 mo)
Tildrakizumab 100 mg
NCT06611163
P3Active, not recruitingModerate to Severe Genital Psoriasis2062026-01-21 (+2 mo)
GL0034 Dose Level 1
NCT07282743
P2RecruitingType II Diabetes Mellitus2852027-04
Abiraterone acetate
NCT05422911
P2RecruitingMetastatic Cancer; Neoplasm, Prostate1922027-12-31 (+30 mo)
TILD sub-cutaneous (SC) injection
NCT04991116
P3Active, not recruitingPsoriatic Arthritis5292028-12 (+60 mo)